319 related articles for article (PubMed ID: 20309546)
1. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen.
Bluemel C; Hausmann S; Fluhr P; Sriskandarajah M; Stallcup WB; Baeuerle PA; Kufer P
Cancer Immunol Immunother; 2010 Aug; 59(8):1197-209. PubMed ID: 20309546
[TBL] [Abstract][Full Text] [Related]
2. Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells.
Torisu-Itakura H; Schoellhammer HF; Sim MS; Irie RF; Hausmann S; Raum T; Baeuerle PA; Morton DL
J Immunother; 2011 Oct; 34(8):597-605. PubMed ID: 21904216
[TBL] [Abstract][Full Text] [Related]
3. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
[TBL] [Abstract][Full Text] [Related]
4. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110.
Petsch S; Gires O; Rüttinger D; Denzel S; Lippold S; Baeuerle PA; Wolf A
MAbs; 2011; 3(1):31-7. PubMed ID: 21107020
[TBL] [Abstract][Full Text] [Related]
5. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.
Deisting W; Raum T; Kufer P; Baeuerle PA; Münz M
PLoS One; 2015; 10(10):e0141669. PubMed ID: 26510188
[TBL] [Abstract][Full Text] [Related]
6. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
7. Melanoma-associated chondroitin sulphate proteoglycan as a new target antigen for CD4+ T cells in melanoma patients.
Erfurt C; Müller E; Emmerling S; Klotz C; Hertl M; Schuler G; Schultz ES
Int J Cancer; 2009 May; 124(10):2341-6. PubMed ID: 19173283
[TBL] [Abstract][Full Text] [Related]
8. A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting.
Schubert I; Kellner C; Stein C; Kügler M; Schwenkert M; Saul D; Stockmeyer B; Berens C; Oduncu FS; Mackensen A; Fey GH
MAbs; 2012; 4(1):45-56. PubMed ID: 22327429
[TBL] [Abstract][Full Text] [Related]
9. A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
Lund ME; Howard CB; Thurecht KJ; Campbell DH; Mahler SM; Walsh BJ
BMC Cancer; 2020 Dec; 20(1):1214. PubMed ID: 33302918
[TBL] [Abstract][Full Text] [Related]
10. Large-Scale Purification of r28M: A Bispecific scFv Antibody Targeting Human Melanoma Produced in Transgenic Cattle.
Spiesberger K; Paulfranz F; Egger A; Reiser J; Vogl C; Rudolf-Scholik J; Mayrhofer C; Grosse-Hovest L; Brem G
PLoS One; 2015; 10(10):e0140471. PubMed ID: 26469402
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers.
Zhang H; Wu Z; Hu D; Yan M; Sun J; Lai J; Bai L
Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891187
[TBL] [Abstract][Full Text] [Related]
12. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance.
Campoli MR; Chang CC; Kageshita T; Wang X; McCarthy JB; Ferrone S
Crit Rev Immunol; 2004; 24(4):267-96. PubMed ID: 15588226
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
Amann M; Brischwein K; Lutterbuese P; Parr L; Petersen L; Lorenczewski G; Krinner E; Bruckmeier S; Lippold S; Kischel R; Lutterbuese R; Kufer P; Baeuerle PA; Schlereth B
Cancer Res; 2008 Jan; 68(1):143-51. PubMed ID: 18172306
[TBL] [Abstract][Full Text] [Related]
14. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.
Rossi DL; Rossi EA; Cardillo TM; Goldenberg DM; Chang CH
MAbs; 2014; 6(2):381-91. PubMed ID: 24492297
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
Schlereth B; Kleindienst P; Fichtner I; Lorenczewski G; Brischwein K; Lippold S; da Silva A; Locher M; Kischel R; Lutterbüse R; Kufer P; Baeuerle PA
Cancer Immunol Immunother; 2006 Jul; 55(7):785-96. PubMed ID: 16187083
[TBL] [Abstract][Full Text] [Related]
16. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
Friedrich M; Raum T; Lutterbuese R; Voelkel M; Deegen P; Rau D; Kischel R; Hoffmann P; Brandl C; Schuhmacher J; Mueller P; Finnern R; Fuergut M; Zopf D; Slootstra JW; Baeuerle PA; Rattel B; Kufer P
Mol Cancer Ther; 2012 Dec; 11(12):2664-73. PubMed ID: 23041545
[TBL] [Abstract][Full Text] [Related]
17. Tumor-reactive CD4+ T cell responses to the melanoma-associated chondroitin sulphate proteoglycan in melanoma patients and healthy individuals in the absence of autoimmunity.
Erfurt C; Sun Z; Haendle I; Schuler-Thurner B; Heirman C; Thielemans K; van der Bruggen P; Schuler G; Schultz ES
J Immunol; 2007 Jun; 178(12):7703-9. PubMed ID: 17548607
[TBL] [Abstract][Full Text] [Related]
18. The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA.
Peng L; Oberst MD; Huang J; Brohawn P; Morehouse C; Lekstrom K; Baeuerle PA; Wu H; Yao Y; Coats SR; Dall'Acqua W; Damschroder M; Hammond SA
PLoS One; 2012; 7(5):e36412. PubMed ID: 22574157
[TBL] [Abstract][Full Text] [Related]
19. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
[TBL] [Abstract][Full Text] [Related]
20. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect
Zhong L; Shi W; Gan L; Liu X; Huo Y; Wu P; Zhang Z; Wu T; Peng H; Huang Y; Zhao Y; Yuan Y; Deng Z; Tang H
Theranostics; 2021; 11(13):6393-6406. PubMed ID: 33995664
[No Abstract] [Full Text] [Related]
[Next] [New Search]